title: [Chemosensitivity testing of oral and maxillofacial cancer with biopsy specimens].
abstract: OBJECTIVE
  To determine the chemosensitivity in fresh biopsy specimen of human oral and maxillofacial cancer, and the differential chemosensitivity among those drugs used popularly in clinic.
  
  
  METHODS
  Human biopsy cancer cells were obtained from 150 oral and maxillofacial malignant tumors. The antitumor drugs tested using modified MTT assay were cisplatin (CDDP), 5-fluorouracil (5-Fu), Pinyangmycin (PYM), Paclitaxel (Taxol), Teniposide (Vm-26), Epi-adriamycin (E-ADM), Vindesin (VDS) and Methortrexatum (MTX).
  
  
  RESULTS
  The success rate of the MTT assay was 93.33% (140 of the 150 cases). At a drug concentration of Cmax x 5, the inhibition rates of oral tumor cells were 63.76% for Vm-26, 25.93% for CDDP, 25.86% for E-ADM, 23.52% for Taxol, 22.97% for PYM, 22.08% for 5-Fu, 18.42% for VDS and 18.93% for MTX. The inhibition rate of VM26 was significantly higher than any of other seven chemotherapeutic drugs (P < 0.05). Over forty percent patients with squamous cell carcinoma showed moderate chemosensitivity to VM-26, CDDP and E-ADM, and over forty percent cases with adenoid carcinoma showed moderate chemosensitivity to Vm-26, Taxol and E-ADM.
  
  
  CONCLUSIONS
  Most oral and maxillofacial cancers showed chemosensitivity to Vm-26, CDDP, E-ADM and Taxol. Vm-26, E-ADM and Taxol were more potent drugs than VDS, 5-Fu and MTX against oral and maxillofacial cancer cells. Chemosensitivity testing using modified MTT assay was useful in selecting antitumor drugs for patients with oral and maxillofacial cancers.
authors.affiliation: Department of Oral and Maxillofacial Surgery, School of Stomatology, Shanghai Second Medical University, Shanghai 200011, China.
authors.forename: Wantao
authors.initials: W
authors.lastname: Chen
authors.forename: Xiaojian
authors.initials: X
authors.lastname: Zhou
authors.forename: Qin
authors.initials: Q
authors.lastname: Xu
authors.forename: Wei
authors.initials: W
authors.lastname: Guo
authors.forename: Lisong
authors.initials: L
authors.lastname: Lin
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001706:Biopsy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D008437:Maxilla / Q000473:pathology; D008441:Maxillary Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009055:Mouth / Q000473:pathology; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000494:pharmacology; D013713:Teniposide / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014751:Vindesine / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D013713:Teniposide; D017239:Paclitaxel; D002945:Cisplatin; D014751:Vindesine; D005472:Fluorouracil